loader

jnj

LATEST ARTICLES
TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care

TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025

Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business

Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business

Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook

Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook

Johnson & Johnson recommends shareholders reject "mini-tender" offer by Tutanota

Johnson & Johnson recommends shareholders reject "mini-tender" offer by Tutanota

Johnson & Johnson to Participate in the UBS Global Healthcare Conference

Johnson & Johnson to Participate in the UBS Global Healthcare Conference

TREMFYA® is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis

TREMFYA® is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis

Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill

Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill

Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses

Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses

U.S. FDA approves TREMFYA® for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

U.S. FDA approves TREMFYA® for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

Latest News

More News

Outlook Reports

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES